Theriva Biologics Announces Orphan Drug Designation Granted By US FDA For VCN-01 For Treatment Of Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics has been granted Orphan Drug Designation by the US FDA for VCN-01, a treatment for pancreatic cancer. The designation will provide various benefits including tax credits, market exclusivity, and FDA assistance for clinical studies.
June 27, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The Orphan Drug Designation granted to Theriva Biologics for VCN-01 could potentially benefit TOVX, if they are associated. The designation could lead to market exclusivity and other benefits that could positively impact the company's financials.
The news does not directly mention TOVX, but if there is an association between Theriva Biologics and TOVX, the Orphan Drug Designation could provide benefits such as market exclusivity, tax credits, and FDA assistance for clinical studies. These benefits could potentially lead to increased revenues and profitability for TOVX, positively impacting its stock price in the short term.
CONFIDENCE 60
IMPORTANCE 70
RELEVANCE 50